JP2018522594A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522594A5
JP2018522594A5 JP2018525816A JP2018525816A JP2018522594A5 JP 2018522594 A5 JP2018522594 A5 JP 2018522594A5 JP 2018525816 A JP2018525816 A JP 2018525816A JP 2018525816 A JP2018525816 A JP 2018525816A JP 2018522594 A5 JP2018522594 A5 JP 2018522594A5
Authority
JP
Japan
Prior art keywords
tumor
lymphocyte
cell
antigen
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018525816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522594A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/ES2016/070597 external-priority patent/WO2017025657A1/es
Publication of JP2018522594A publication Critical patent/JP2018522594A/ja
Publication of JP2018522594A5 publication Critical patent/JP2018522594A5/ja
Pending legal-status Critical Current

Links

JP2018525816A 2015-08-07 2016-08-08 抗腫瘍治療のための、トランスインフェクションさせたリンパ球 Pending JP2018522594A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201531177 2015-08-07
ESP201531177 2015-08-07
PCT/ES2016/070597 WO2017025657A1 (es) 2015-08-07 2016-08-08 Linfocitos transinfectados para terapia anti-tumoral

Publications (2)

Publication Number Publication Date
JP2018522594A JP2018522594A (ja) 2018-08-16
JP2018522594A5 true JP2018522594A5 (enExample) 2019-09-12

Family

ID=56936436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018525816A Pending JP2018522594A (ja) 2015-08-07 2016-08-08 抗腫瘍治療のための、トランスインフェクションさせたリンパ球

Country Status (6)

Country Link
US (1) US20180228840A1 (enExample)
EP (1) EP3333255A1 (enExample)
JP (1) JP2018522594A (enExample)
AU (1) AU2016307370A1 (enExample)
CA (1) CA2995021A1 (enExample)
WO (1) WO2017025657A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12087428B2 (en) * 2020-12-29 2024-09-10 Kpn Innovations Llc Systems and methods for generating a body degradation reduction program

Similar Documents

Publication Publication Date Title
Wylie et al. Dendritic cells and cancer: from biology to therapeutic intervention
Uribe-Herranz et al. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12
Hirohashi et al. Immune responses to human cancer stem‐like cells/cancer‐initiating cells
Janikashvili et al. The dendritic cell‐regulatory T lymphocyte crosstalk contributes to tumor‐induced tolerance
Dar et al. Insights into the relationship between toll like receptors and gamma delta T cell responses
ES2816450T3 (es) Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR
Karantanos et al. Regulation of T cell differentiation and function by EZH2
Matsui et al. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity
Fensterle et al. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B
Alizadeh et al. The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer
De Vries et al. The immunogenicity of colorectal cancer in relation to tumor development and treatment
EP4495133A3 (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
CN108884468A (zh) 基于个性化递送载体的免疫疗法及其用途
JP2009518021A5 (enExample)
AU2018244371A8 (en) Methods of isolating neoantigen-specific T cell receptor sequences
Ancuta et al. Th17 lineage commitment and HIV-1 pathogenesis
Li et al. Characteristics of CD8+ and CD4+ tissue‐resident memory lymphocytes in the gastrointestinal tract
Wilczynski et al. Cancer immunoediting: elimination, equilibrium, and immune escape in solid tumors
Kitagawa et al. An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model
Lhotakova et al. Establishment and characterization of a mouse tumor cell line with irreversible downregulation of MHC class I molecules
Denies et al. Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs
Fu et al. Dendritic cells loaded with CD44+ CT-26 colon cell lysate evoke potent antitumor immune responses
Chen et al. Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery
Balevičiūtė et al. High-frequency nanosecond bleomycin electrochemotherapy and its effects on changes in the immune system and survival
JP2018522594A5 (enExample)